Notice Information
Notice Title
NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)
Notice Description
Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland.
Lot Information
Standard Half-life Recombinant Factor VIII
NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Enhanced Half-life Recombinant Factor VIIINHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Enhanced Half-life Recombinant Factor VIIINHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Eftrenonacog alfa (rFIX EHL)NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Eftrenonacog alfa (rFIX EHL)NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Nonacog beta pegol (rFIX EHL)NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
rFIX - Standard Half LifeNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Recombinant Factor VIINHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Porcine Factor VIII - susoctocog alfaNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Factor VIII Inhibitor Bypassing FractionNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Factor IX - High Purity Factor IXNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Factor XNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Factor XIII - Plasma DerivedNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Factor XIII - RecombinantNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Von willebrands factor / Factor VIIINHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Von willebrands factor - Plasma DerivedNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Von willebrands factor - RecombinantNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Fibrinogen ConcentrateNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Prothrombin Complex driedNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Protein C ConcentrateNHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Fresh Frozen Plasma (all blood groups)NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-r6ebe6-0000772000
- Publication Source
- Public Contracts Scotland
- Latest Notice
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597
- Current Stage
- Award
- All Stages
- Award
Procurement Classification
- Notice Type
- PCS Notice - Website Contract Award Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33141530 - Blood coagulants
33600000 - Pharmaceutical products
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £85,293,871 £10M-£100M
Notice Dates
- Publication Date
- 10 Jul 20241 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- Not specified
- Award Date
- 31 May 20241 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Complete
- Awards Status
- Not Specified
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)
- Contact Name
- Not specified
- Contact Email
- michael.walker3@nhs.scot
- Contact Phone
- +44 7919392110
Buyer Location
- Locality
- EDINBURGH
- Postcode
- EH12 9EB
- Post Town
- Edinburgh
- Country
- Scotland
-
- Major Region (ITL 1)
- TLM Scotland
- Basic Region (ITL 2)
- TLM1 East Central Scotland
- Small Region (ITL 3)
- TLM13 City of Edinburgh
- Delivery Location
- TLM Scotland
-
- Local Authority
- City of Edinburgh
- Electoral Ward
- Drum Brae/Gyle
- Westminster Constituency
- Edinburgh South West
Further Information
Notice Documents
-
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597
NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661) - Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland.
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-r6ebe6-0000772000-2024-07-10T00:00:00Z",
"date": "2024-07-10T00:00:00Z",
"ocid": "ocds-r6ebe6-0000772000",
"initiationType": "tender",
"parties": [
{
"id": "org-198",
"name": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)",
"identifier": {
"legalName": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)"
},
"address": {
"streetAddress": "Gyle Square, 1 South Gyle Crescent",
"locality": "Edinburgh",
"region": "UKM",
"postalCode": "EH12 9EB"
},
"contactPoint": {
"email": "michael.walker3@nhs.scot",
"telephone": "+44 7919392110",
"url": "http://"
},
"roles": [
"buyer",
"centralPurchasingBody"
],
"details": {
"classifications": [
{
"id": "Body governed by public law",
"scheme": "TED_CA_TYPE"
},
{
"id": "07",
"description": "Health",
"scheme": "COFOG"
}
],
"url": "http://www.nss.nhs.scot/browse/procurement-and-logistics"
}
},
{
"id": "org-317",
"name": "Takeda UK Limited",
"identifier": {
"legalName": "Takeda UK Limited"
},
"address": {
"streetAddress": "Takeda House, Mercury Park, Wycombe Lane, Wooburn Green",
"locality": "High Wycombe, Bucks",
"region": "UK",
"postalCode": "HP10 0HH"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-318",
"name": "Pfizer Limited",
"identifier": {
"legalName": "Pfizer Limited"
},
"address": {
"streetAddress": "Walton Oaks, Dorking Road",
"locality": "Tadworth",
"region": "UK",
"postalCode": "KT20 7NS"
},
"contactPoint": {
"telephone": "+44 7748322101"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-319",
"name": "Octapharma Ltd",
"identifier": {
"legalName": "Octapharma Ltd"
},
"address": {
"streetAddress": "Octapharma Ltd, The Zenith Building, 26 Spring Gardens",
"locality": "Manchester",
"region": "UK",
"postalCode": "M2 1AB"
},
"contactPoint": {
"telephone": "+44 7885995899"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-320",
"name": "Bio Products Laboratory",
"identifier": {
"legalName": "Bio Products Laboratory"
},
"address": {
"streetAddress": "Dagger Lane, Elstree",
"locality": "Hertfordshire",
"region": "UK",
"postalCode": "WD6 3BX"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-321",
"name": "CSL Behring",
"identifier": {
"legalName": "CSL Behring"
},
"address": {
"streetAddress": "4 Milton road",
"locality": "Haywards Heath",
"region": "UKJ27",
"postalCode": "RH16 1AH"
},
"contactPoint": {
"telephone": "+44 7827837466"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-322",
"name": "Novo Nordisk Ltd",
"identifier": {
"legalName": "Novo Nordisk Ltd"
},
"address": {
"streetAddress": "3 City Place, Beehive Ring Road",
"locality": "Gatwick",
"region": "UKJ",
"postalCode": "RH6 0PA"
},
"contactPoint": {
"telephone": "+44 1293762293"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-323",
"name": "LFB Biopharmaceuticals Ltd",
"identifier": {
"legalName": "LFB Biopharmaceuticals Ltd"
},
"address": {
"streetAddress": "PO Box 63587",
"locality": "London",
"region": "UKI",
"postalCode": "N6 9BR"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-324",
"name": "Swedish Orphan Biovitrum Ltd",
"identifier": {
"legalName": "Swedish Orphan Biovitrum Ltd"
},
"address": {
"streetAddress": "Suite 2, Riverside 3, Granta Park, , Great Abington",
"locality": "Cambridgshire",
"region": "UK",
"postalCode": "CB21 6AD"
},
"contactPoint": {
"telephone": "+44 7773969509"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-325",
"name": "Roche Products Ltd",
"identifier": {
"legalName": "Roche Products Ltd"
},
"address": {
"streetAddress": "6 Falcon Way, Shire Park",
"locality": "Welwyn Garden City",
"region": "UK",
"postalCode": "AL7 1TW"
},
"contactPoint": {
"telephone": "+44 1707366171"
},
"roles": [
"supplier"
],
"details": {
"scale": "large",
"url": "http://"
}
},
{
"id": "org-33",
"name": "Sheriff Court House",
"identifier": {
"legalName": "Sheriff Court House"
},
"address": {
"streetAddress": "27 Chambers Street",
"locality": "Edinburgh",
"postalCode": "EH1 1LB"
},
"contactPoint": {
"telephone": "+44 1312252525",
"url": "http://"
},
"roles": [
"reviewBody"
]
}
],
"buyer": {
"name": "The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)",
"id": "org-198"
},
"tender": {
"id": "ocds-r6ebe6-0000772000",
"title": "NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)",
"description": "Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland.",
"status": "complete",
"items": [
{
"id": "1",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "1"
},
{
"id": "2",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "2"
},
{
"id": "3",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "3"
},
{
"id": "4",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "4"
},
{
"id": "5",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "5"
},
{
"id": "6",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "6"
},
{
"id": "7",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "7"
},
{
"id": "8",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "8"
},
{
"id": "9",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "9"
},
{
"id": "10",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "10"
},
{
"id": "11",
"additionalClassifications": [
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "11"
},
{
"id": "12",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "12"
},
{
"id": "13",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "13"
},
{
"id": "14",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "14"
},
{
"id": "15",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "15"
},
{
"id": "16",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "16"
},
{
"id": "17",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "17"
},
{
"id": "18",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "18"
},
{
"id": "19",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "19"
},
{
"id": "20",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "20"
},
{
"id": "21",
"additionalClassifications": [
{
"id": "33600000",
"scheme": "CPV"
},
{
"id": "33141530",
"scheme": "CPV"
}
],
"deliveryLocation": {
"description": "All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014."
},
"deliveryAddresses": [
{
"region": "UKM"
}
],
"relatedLot": "21"
}
],
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"mainProcurementCategory": "goods",
"documents": [
{
"id": "JUL509597",
"documentType": "awardNotice",
"title": "NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)",
"description": "Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland.",
"url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUL509597",
"format": "text/html"
}
],
"lots": [
{
"id": "1",
"title": "Standard Half-life Recombinant Factor VIII",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "2",
"title": "Enhanced Half-life Recombinant Factor VIII",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "3",
"title": "Enhanced Half-life Recombinant Factor VIII",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "4",
"title": "Eftrenonacog alfa (rFIX EHL)",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "5",
"title": "Eftrenonacog alfa (rFIX EHL)",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "6",
"title": "Nonacog beta pegol (rFIX EHL)",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "7",
"title": "rFIX - Standard Half Life",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "8",
"title": "Recombinant Factor VII",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "9",
"title": "Porcine Factor VIII - susoctocog alfa",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "10",
"title": "Factor VIII Inhibitor Bypassing Fraction",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "11",
"title": "Factor IX - High Purity Factor IX",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "12",
"title": "Factor X",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "13",
"title": "Factor XIII - Plasma Derived",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "14",
"title": "Factor XIII - Recombinant",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "15",
"title": "Von willebrands factor / Factor VIII",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "16",
"title": "Von willebrands factor - Plasma Derived",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "17",
"title": "Von willebrands factor - Recombinant",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "18",
"title": "Fibrinogen Concentrate",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "19",
"title": "Prothrombin Complex dried",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "20",
"title": "Protein C Concentrate",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
},
{
"id": "21",
"title": "Fresh Frozen Plasma (all blood groups)",
"description": "NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.",
"status": "complete",
"hasOptions": false
}
],
"coveredBy": [
"GPA"
],
"techniques": {
"hasFrameworkAgreement": true
},
"classification": {
"id": "33600000",
"scheme": "CPV"
},
"reviewDetails": "Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts: An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session. The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages."
},
"awards": [
{
"id": "ocds-r6ebe6-0000772000-1",
"title": "Standard Half-life Recombinant Factor VIII",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
},
{
"id": "org-318",
"name": "Pfizer Limited"
},
{
"id": "org-319",
"name": "Octapharma Ltd"
}
],
"relatedLots": [
"1"
]
},
{
"id": "ocds-r6ebe6-0000772000-2",
"title": "Factor VIII Inhibitor Bypassing Fraction",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
}
],
"relatedLots": [
"10"
]
},
{
"id": "ocds-r6ebe6-0000772000-3",
"title": "Factor IX - High Purity Factor IX",
"suppliers": [
{
"id": "org-320",
"name": "Bio Products Laboratory"
}
],
"relatedLots": [
"11"
]
},
{
"id": "ocds-r6ebe6-0000772000-4",
"title": "Factor X",
"suppliers": [
{
"id": "org-320",
"name": "Bio Products Laboratory"
}
],
"relatedLots": [
"12"
]
},
{
"id": "ocds-r6ebe6-0000772000-5",
"title": "Factor XIII - Plasma Derived",
"suppliers": [
{
"id": "org-321",
"name": "CSL Behring"
}
],
"relatedLots": [
"13"
]
},
{
"id": "ocds-r6ebe6-0000772000-6",
"title": "Factor XIII - Recombinant",
"suppliers": [
{
"id": "org-322",
"name": "Novo Nordisk Ltd"
}
],
"relatedLots": [
"14"
]
},
{
"id": "ocds-r6ebe6-0000772000-7",
"title": "Von willebrands factor / Factor VIII",
"suppliers": [
{
"id": "org-319",
"name": "Octapharma Ltd"
},
{
"id": "org-321",
"name": "CSL Behring"
}
],
"relatedLots": [
"15"
]
},
{
"id": "ocds-r6ebe6-0000772000-8",
"title": "Von willebrands factor - Plasma Derived",
"suppliers": [
{
"id": "org-323",
"name": "LFB Biopharmaceuticals Ltd"
}
],
"relatedLots": [
"16"
]
},
{
"id": "ocds-r6ebe6-0000772000-9",
"title": "Von willebrands factor - Recombinant",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
}
],
"relatedLots": [
"17"
]
},
{
"id": "ocds-r6ebe6-0000772000-10",
"title": "Fibrinogen Concentrate",
"suppliers": [
{
"id": "org-319",
"name": "Octapharma Ltd"
},
{
"id": "org-321",
"name": "CSL Behring"
},
{
"id": "org-323",
"name": "LFB Biopharmaceuticals Ltd"
}
],
"relatedLots": [
"18"
]
},
{
"id": "ocds-r6ebe6-0000772000-11",
"title": "Prothrombin Complex dried",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
},
{
"id": "org-319",
"name": "Octapharma Ltd"
},
{
"id": "org-321",
"name": "CSL Behring"
}
],
"relatedLots": [
"19"
]
},
{
"id": "ocds-r6ebe6-0000772000-12",
"title": "Enhanced Half-life Recombinant Factor VIII",
"suppliers": [
{
"id": "org-322",
"name": "Novo Nordisk Ltd"
},
{
"id": "org-324",
"name": "Swedish Orphan Biovitrum Ltd"
}
],
"relatedLots": [
"2"
]
},
{
"id": "ocds-r6ebe6-0000772000-13",
"title": "Protein C Concentrate",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
}
],
"relatedLots": [
"20"
]
},
{
"id": "ocds-r6ebe6-0000772000-14",
"title": "Fresh Frozen Plasma (all blood groups)",
"suppliers": [
{
"id": "org-319",
"name": "Octapharma Ltd"
}
],
"relatedLots": [
"21"
]
},
{
"id": "ocds-r6ebe6-0000772000-15",
"title": "Enhanced Half-life Recombinant Factor VIII",
"suppliers": [
{
"id": "org-325",
"name": "Roche Products Ltd"
}
],
"relatedLots": [
"3"
]
},
{
"id": "ocds-r6ebe6-0000772000-16",
"title": "Eftrenonacog alfa (rFIX EHL)",
"suppliers": [
{
"id": "org-324",
"name": "Swedish Orphan Biovitrum Ltd"
}
],
"relatedLots": [
"4"
]
},
{
"id": "ocds-r6ebe6-0000772000-17",
"title": "Eftrenonacog alfa (rFIX EHL)",
"suppliers": [
{
"id": "org-321",
"name": "CSL Behring"
}
],
"relatedLots": [
"5"
]
},
{
"id": "ocds-r6ebe6-0000772000-18",
"title": "Nonacog beta pegol (rFIX EHL)",
"suppliers": [
{
"id": "org-322",
"name": "Novo Nordisk Ltd"
}
],
"relatedLots": [
"6"
]
},
{
"id": "ocds-r6ebe6-0000772000-19",
"title": "rFIX - Standard Half Life",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
},
{
"id": "org-318",
"name": "Pfizer Limited"
}
],
"relatedLots": [
"7"
]
},
{
"id": "ocds-r6ebe6-0000772000-20",
"title": "Recombinant Factor VII",
"suppliers": [
{
"id": "org-322",
"name": "Novo Nordisk Ltd"
},
{
"id": "org-323",
"name": "LFB Biopharmaceuticals Ltd"
}
],
"relatedLots": [
"8"
]
},
{
"id": "ocds-r6ebe6-0000772000-21",
"title": "Porcine Factor VIII - susoctocog alfa",
"suppliers": [
{
"id": "org-317",
"name": "Takeda UK Limited"
}
],
"relatedLots": [
"9"
]
}
],
"contracts": [
{
"id": "ocds-r6ebe6-0000772000-1",
"awardID": "ocds-r6ebe6-0000772000-1",
"title": "Standard Half-life Recombinant Factor VIII",
"status": "active",
"value": {
"amount": 9070137,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-2",
"awardID": "ocds-r6ebe6-0000772000-2",
"title": "Factor VIII Inhibitor Bypassing Fraction",
"status": "active",
"value": {
"amount": 502964,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-3",
"awardID": "ocds-r6ebe6-0000772000-3",
"title": "Factor IX - High Purity Factor IX",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-4",
"awardID": "ocds-r6ebe6-0000772000-4",
"title": "Factor X",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-5",
"awardID": "ocds-r6ebe6-0000772000-5",
"title": "Factor XIII - Plasma Derived",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-6",
"awardID": "ocds-r6ebe6-0000772000-6",
"title": "Factor XIII - Recombinant",
"status": "active",
"value": {
"amount": 129113,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-7",
"awardID": "ocds-r6ebe6-0000772000-7",
"title": "Von willebrands factor / Factor VIII",
"status": "active",
"value": {
"amount": 532441,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-8",
"awardID": "ocds-r6ebe6-0000772000-8",
"title": "Von willebrands factor - Plasma Derived",
"status": "active",
"value": {
"amount": 1196460,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-9",
"awardID": "ocds-r6ebe6-0000772000-9",
"title": "Von willebrands factor - Recombinant",
"status": "active",
"value": {
"amount": 2815053,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-10",
"awardID": "ocds-r6ebe6-0000772000-10",
"title": "Fibrinogen Concentrate",
"status": "active",
"value": {
"amount": 186346,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-11",
"awardID": "ocds-r6ebe6-0000772000-11",
"title": "Prothrombin Complex dried",
"status": "active",
"value": {
"amount": 1380752,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-12",
"awardID": "ocds-r6ebe6-0000772000-12",
"title": "Enhanced Half-life Recombinant Factor VIII",
"status": "active",
"value": {
"amount": 7134755,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-13",
"awardID": "ocds-r6ebe6-0000772000-13",
"title": "Protein C Concentrate",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-14",
"awardID": "ocds-r6ebe6-0000772000-14",
"title": "Fresh Frozen Plasma (all blood groups)",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-15",
"awardID": "ocds-r6ebe6-0000772000-15",
"title": "Enhanced Half-life Recombinant Factor VIII",
"status": "active",
"value": {
"amount": 40327988,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-16",
"awardID": "ocds-r6ebe6-0000772000-16",
"title": "Eftrenonacog alfa (rFIX EHL)",
"status": "active",
"value": {
"amount": 1674113,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-17",
"awardID": "ocds-r6ebe6-0000772000-17",
"title": "Eftrenonacog alfa (rFIX EHL)",
"status": "active",
"value": {
"amount": 14643514,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-18",
"awardID": "ocds-r6ebe6-0000772000-18",
"title": "Nonacog beta pegol (rFIX EHL)",
"status": "active",
"value": {
"amount": 490820,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-19",
"awardID": "ocds-r6ebe6-0000772000-19",
"title": "rFIX - Standard Half Life",
"status": "active",
"value": {
"amount": 4604830,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-20",
"awardID": "ocds-r6ebe6-0000772000-20",
"title": "Recombinant Factor VII",
"status": "active",
"value": {
"amount": 604584,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
},
{
"id": "ocds-r6ebe6-0000772000-21",
"awardID": "ocds-r6ebe6-0000772000-21",
"title": "Porcine Factor VIII - susoctocog alfa",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2024-05-31T00:00:00Z"
}
],
"language": "EN",
"description": "Award against framework: Blood Disorders including Haemophilia A & B (Ref: CM/PHS/22/5661) Award against MPSU (NHSE) Framework Agreement: Blood Disorders including Haemophilia A & B (Ref: CM/PHS/22/5661) The estimated value(s) referred to in Section II.1.7 and Section V.2.4 covers the thirty-four (34) month Framework Agreement duration and the fourteen (14) month extension period of the Framework Agreement. Where an estimated value of 1 GBP is provided in Section V.2.4, there is no estimated usage of Goods within the specified Lot. These nominal values are not included in the overall estimated value referred to in Section II.1.7. Further details of award criteria and weightings for the Framework Agreement (which were shared within the procurement documentation) can be requested from the named person at the head of this notice. (SC Ref:772000)",
"bids": {
"statistics": [
{
"id": "1016",
"measure": "bids",
"value": 3,
"relatedLot": "1"
},
{
"id": "1017",
"measure": "smeBids",
"value": 0,
"relatedLot": "1"
},
{
"id": "1018",
"measure": "foreignBidsFromEU",
"value": 3,
"relatedLot": "1"
},
{
"id": "1019",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "1"
},
{
"id": "1020",
"measure": "electronicBids",
"value": 3,
"relatedLot": "1"
},
{
"id": "1021",
"measure": "bids",
"value": 1,
"relatedLot": "10"
},
{
"id": "1022",
"measure": "smeBids",
"value": 0,
"relatedLot": "10"
},
{
"id": "1023",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "10"
},
{
"id": "1024",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "10"
},
{
"id": "1025",
"measure": "electronicBids",
"value": 1,
"relatedLot": "10"
},
{
"id": "1026",
"measure": "bids",
"value": 1,
"relatedLot": "11"
},
{
"id": "1027",
"measure": "smeBids",
"value": 0,
"relatedLot": "11"
},
{
"id": "1028",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "11"
},
{
"id": "1029",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "11"
},
{
"id": "1030",
"measure": "electronicBids",
"value": 1,
"relatedLot": "11"
},
{
"id": "1031",
"measure": "bids",
"value": 1,
"relatedLot": "12"
},
{
"id": "1032",
"measure": "smeBids",
"value": 0,
"relatedLot": "12"
},
{
"id": "1033",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "12"
},
{
"id": "1034",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "12"
},
{
"id": "1035",
"measure": "electronicBids",
"value": 1,
"relatedLot": "12"
},
{
"id": "1036",
"measure": "bids",
"value": 1,
"relatedLot": "13"
},
{
"id": "1037",
"measure": "smeBids",
"value": 0,
"relatedLot": "13"
},
{
"id": "1038",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "13"
},
{
"id": "1039",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "13"
},
{
"id": "1040",
"measure": "electronicBids",
"value": 1,
"relatedLot": "13"
},
{
"id": "1041",
"measure": "bids",
"value": 1,
"relatedLot": "14"
},
{
"id": "1042",
"measure": "smeBids",
"value": 0,
"relatedLot": "14"
},
{
"id": "1043",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "14"
},
{
"id": "1044",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "14"
},
{
"id": "1045",
"measure": "electronicBids",
"value": 1,
"relatedLot": "14"
},
{
"id": "1046",
"measure": "bids",
"value": 2,
"relatedLot": "15"
},
{
"id": "1047",
"measure": "smeBids",
"value": 0,
"relatedLot": "15"
},
{
"id": "1048",
"measure": "foreignBidsFromEU",
"value": 2,
"relatedLot": "15"
},
{
"id": "1049",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "15"
},
{
"id": "1050",
"measure": "electronicBids",
"value": 2,
"relatedLot": "15"
},
{
"id": "1051",
"measure": "bids",
"value": 1,
"relatedLot": "16"
},
{
"id": "1052",
"measure": "smeBids",
"value": 0,
"relatedLot": "16"
},
{
"id": "1053",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "16"
},
{
"id": "1054",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "16"
},
{
"id": "1055",
"measure": "electronicBids",
"value": 1,
"relatedLot": "16"
},
{
"id": "1056",
"measure": "bids",
"value": 1,
"relatedLot": "17"
},
{
"id": "1057",
"measure": "smeBids",
"value": 0,
"relatedLot": "17"
},
{
"id": "1058",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "17"
},
{
"id": "1059",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "17"
},
{
"id": "1060",
"measure": "electronicBids",
"value": 1,
"relatedLot": "17"
},
{
"id": "1061",
"measure": "bids",
"value": 3,
"relatedLot": "18"
},
{
"id": "1062",
"measure": "smeBids",
"value": 0,
"relatedLot": "18"
},
{
"id": "1063",
"measure": "foreignBidsFromEU",
"value": 3,
"relatedLot": "18"
},
{
"id": "1064",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "18"
},
{
"id": "1065",
"measure": "electronicBids",
"value": 3,
"relatedLot": "18"
},
{
"id": "1066",
"measure": "bids",
"value": 2,
"relatedLot": "19"
},
{
"id": "1067",
"measure": "smeBids",
"value": 0,
"relatedLot": "19"
},
{
"id": "1068",
"measure": "foreignBidsFromEU",
"value": 2,
"relatedLot": "19"
},
{
"id": "1069",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "19"
},
{
"id": "1070",
"measure": "electronicBids",
"value": 2,
"relatedLot": "19"
},
{
"id": "1071",
"measure": "bids",
"value": 2,
"relatedLot": "2"
},
{
"id": "1072",
"measure": "smeBids",
"value": 0,
"relatedLot": "2"
},
{
"id": "1073",
"measure": "foreignBidsFromEU",
"value": 2,
"relatedLot": "2"
},
{
"id": "1074",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "2"
},
{
"id": "1075",
"measure": "electronicBids",
"value": 2,
"relatedLot": "2"
},
{
"id": "1076",
"measure": "bids",
"value": 1,
"relatedLot": "20"
},
{
"id": "1077",
"measure": "smeBids",
"value": 0,
"relatedLot": "20"
},
{
"id": "1078",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "20"
},
{
"id": "1079",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "20"
},
{
"id": "1080",
"measure": "electronicBids",
"value": 1,
"relatedLot": "20"
},
{
"id": "1081",
"measure": "bids",
"value": 1,
"relatedLot": "21"
},
{
"id": "1082",
"measure": "smeBids",
"value": 0,
"relatedLot": "21"
},
{
"id": "1083",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "21"
},
{
"id": "1084",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "21"
},
{
"id": "1085",
"measure": "electronicBids",
"value": 1,
"relatedLot": "21"
},
{
"id": "1086",
"measure": "bids",
"value": 1,
"relatedLot": "3"
},
{
"id": "1087",
"measure": "smeBids",
"value": 0,
"relatedLot": "3"
},
{
"id": "1088",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "3"
},
{
"id": "1089",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "3"
},
{
"id": "1090",
"measure": "electronicBids",
"value": 1,
"relatedLot": "3"
},
{
"id": "1091",
"measure": "bids",
"value": 1,
"relatedLot": "4"
},
{
"id": "1092",
"measure": "smeBids",
"value": 0,
"relatedLot": "4"
},
{
"id": "1093",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "4"
},
{
"id": "1094",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "4"
},
{
"id": "1095",
"measure": "electronicBids",
"value": 1,
"relatedLot": "4"
},
{
"id": "1096",
"measure": "bids",
"value": 1,
"relatedLot": "5"
},
{
"id": "1097",
"measure": "smeBids",
"value": 0,
"relatedLot": "5"
},
{
"id": "1098",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "5"
},
{
"id": "1099",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "5"
},
{
"id": "1100",
"measure": "electronicBids",
"value": 1,
"relatedLot": "5"
},
{
"id": "1101",
"measure": "bids",
"value": 1,
"relatedLot": "6"
},
{
"id": "1102",
"measure": "smeBids",
"value": 0,
"relatedLot": "6"
},
{
"id": "1103",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "6"
},
{
"id": "1104",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "6"
},
{
"id": "1105",
"measure": "electronicBids",
"value": 1,
"relatedLot": "6"
},
{
"id": "1106",
"measure": "bids",
"value": 2,
"relatedLot": "7"
},
{
"id": "1107",
"measure": "smeBids",
"value": 0,
"relatedLot": "7"
},
{
"id": "1108",
"measure": "foreignBidsFromEU",
"value": 2,
"relatedLot": "7"
},
{
"id": "1109",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "7"
},
{
"id": "1110",
"measure": "electronicBids",
"value": 2,
"relatedLot": "7"
},
{
"id": "1111",
"measure": "bids",
"value": 2,
"relatedLot": "8"
},
{
"id": "1112",
"measure": "smeBids",
"value": 0,
"relatedLot": "8"
},
{
"id": "1113",
"measure": "foreignBidsFromEU",
"value": 2,
"relatedLot": "8"
},
{
"id": "1114",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "8"
},
{
"id": "1115",
"measure": "electronicBids",
"value": 2,
"relatedLot": "8"
},
{
"id": "1116",
"measure": "bids",
"value": 1,
"relatedLot": "9"
},
{
"id": "1117",
"measure": "smeBids",
"value": 0,
"relatedLot": "9"
},
{
"id": "1118",
"measure": "foreignBidsFromEU",
"value": 1,
"relatedLot": "9"
},
{
"id": "1119",
"measure": "foreignBidsFromNonEU",
"value": 0,
"relatedLot": "9"
},
{
"id": "1120",
"measure": "electronicBids",
"value": 1,
"relatedLot": "9"
}
]
},
"links": [
{
"rel": "canonical",
"href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000772000"
}
],
"noticetype": "PCS Notice - Website Contract Award Notice"
}